These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35857410)

  • 21. Letter to the Editor: Comment on ''Cytoreductive Surgery with or without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial''.
    Carneiro VCG; Ramalho NM
    Ann Surg Oncol; 2022 May; 29(5):3351-3352. PubMed ID: 35166953
    [No Abstract]   [Full Text] [Related]  

  • 22. Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.
    Koole SN; Bruijs L; Fabris C; Sikorska K; Engbersen M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; van der Velden J; Arts HJG; van Ham M; Van Dam P; Vuylsteke P; Lahaye M; Sonke G; Driel WV
    Int J Gynecol Cancer; 2020 Dec; 30(12):1928-1934. PubMed ID: 33046576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIPEC in advanced epithelial ovarian cancer: why is there controversy?
    Vermorken JB; van Dam P; Brand A
    Curr Opin Oncol; 2020 Sep; 32(5):451-458. PubMed ID: 32675595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    Kim SI; Kim JW
    ESMO Open; 2021 Jun; 6(3):100149. PubMed ID: 33984680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: long-term findings from the OVHIPEC-1 trial.
    Ghirardi V; Fagotti A; Scambia G
    Lancet Oncol; 2023 Oct; 24(10):1057-1059. PubMed ID: 37797627
    [No Abstract]   [Full Text] [Related]  

  • 27. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update.
    Revaux A; Carbonnel M; Kanso F; Naoura I; Asmar J; Kadhel P; Ayoubi JM
    Horm Mol Biol Clin Investig; 2020 Feb; 41(3):. PubMed ID: 32083444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
    El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
    ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
    Ghirardi V; Ronsini C; Trozzi R; Di Ilio C; Di Giorgio A; Cianci S; Draisci G; Scambia G; Fagotti A
    Cancer; 2020 Dec; 126(24):5256-5262. PubMed ID: 32931024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.
    Vos LMC; Aronson SL; van Driel WJ; Huitema ADR; Schagen van Leeuwen JH; Lok CAR; Sonke GS
    Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():86-102. PubMed ID: 34565676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial".
    Noiret B; Bakrin N; Eveno C
    Ann Surg Oncol; 2022 May; 29(5):3357-3358. PubMed ID: 35192155
    [No Abstract]   [Full Text] [Related]  

  • 32. The Debatable Role of HIPEC in Ovarian Cancer.
    Paulino E; Melo AC
    Ann Surg Oncol; 2022 May; 29(5):3353-3354. PubMed ID: 35254576
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.
    Ceresoli M; Verrengia A; Montori G; Busci L; Coccolini F; Ansaloni L; Frigerio L
    J Gynecol Oncol; 2018 May; 29(3):e53. PubMed ID: 29533028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraperitoneal chemotherapy: Hot, timely, and relevant?
    Mackay HJ; Kohn EC
    Cancer; 2020 Dec; 126(24):5206-5209. PubMed ID: 32931026
    [No Abstract]   [Full Text] [Related]  

  • 35. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Bouchard-Fortier G; Cusimano MC; Fazelzad R; Sajewycz K; Lu L; Espin-Garcia O; May T; Bouchard-Fortier A; Ferguson SE
    Gynecol Oncol; 2020 Jul; 158(1):218-228. PubMed ID: 32387131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peritoneal carcinomatosis from ovarian carcinoma treated by interval laparoscopic complete cytoreduction and HIPEC with extraction through natural orifice.
    Arjona-Sánchez Á; Durán M; Sánchez-Hidalgo JM; Rufian-Peña S
    Surg Oncol; 2019 Dec; 31():14-15. PubMed ID: 31472328
    [No Abstract]   [Full Text] [Related]  

  • 38. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
    Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
    Lim SL; Havrilesky LJ; Habib AS; Secord AA
    Gynecol Oncol; 2019 May; 153(2):376-380. PubMed ID: 30718126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.
    Cascales Campos PA; González Gil A
    Ann Surg Oncol; 2022 May; 29(5):3361-3362. PubMed ID: 35254577
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.